SEATTLE — The investigational integrase inhibitor bictegravir worked as well as dolutegravir (Tivicay) and caused no serious side effects when used as part of a three-drug antiretroviral therapy regimen, a researcher said here. Bictegravir is now being evaluated in phase III studies. Viral suppression rates were high in both treatment arms and no one taking...
Tag: <span>bictegravir</span>
Post
Gilead HIV drug aces phase 2, teeing up tussle with GSK
Gilead is looking to bictegravir to defend its HIV franchise against GSK Gilead has posted upbeat phase 2 data on its next-generation integrase inhibitor bictegravir in HIV patients. The drug more than held its own against GlaxoSmithKline’s dolutegravir, setting the stage for a larger-scale comparison in phase 3 and potential scrap for a multibillion-dollar market. The trial...